MedTrace Logo

Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 003

NCT01661751 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2012-08-09

No results posted yet for this study

Summary

The clinical trial was designed to evaluate the safety and immunogenicity against Group ACYW135 Meningococcal Polysaccharide Vaccine of Hualan administered on subjects 2 years of age and older.

Conditions

Interventions

BIOLOGICAL

ACYW135 Meningococcal Polysaccharide Vaccine

600 subjects were divided into three groups (200 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime

BIOLOGICAL

A+C Meningococcal Polysaccharide Vaccine

300 subjects were divided into three groups (100 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime

Sponsors & Collaborators

  • Hualan Biological Engineering, Inc.

    lead INDUSTRY

Principal Investigators

  • Fubao Ma, Bachelor · Immunization Program Institute of Jiangsu Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2006-05-31
Completion
2006-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01661751 on ClinicalTrials.gov